Deutsche Bank AG Raises Stock Holdings in Akoya Biosciences, Inc. (NASDAQ:AKYA)

Deutsche Bank AG boosted its holdings in Akoya Biosciences, Inc. (NASDAQ:AKYA) by 404.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 54,788 shares of the company’s stock after purchasing an additional 43,920 shares during the quarter. Deutsche Bank AG owned approximately 0.11% of Akoya Biosciences worth $125,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of AKYA. Bank of America Corp DE grew its stake in shares of Akoya Biosciences by 39.6% in the fourth quarter. Bank of America Corp DE now owns 29,092 shares of the company’s stock valued at $67,000 after buying an additional 8,258 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Akoya Biosciences by 18.9% in the 4th quarter. Northern Trust Corp now owns 250,343 shares of the company’s stock worth $573,000 after purchasing an additional 39,799 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Akoya Biosciences during the 4th quarter valued at $31,000. Paragon Associates & Paragon Associates II Joint Venture raised its stake in Akoya Biosciences by 1.4% during the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 801,000 shares of the company’s stock valued at $1,834,000 after acquiring an additional 11,000 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Akoya Biosciences by 295.4% during the 4th quarter. JPMorgan Chase & Co. now owns 48,313 shares of the company’s stock valued at $111,000 after acquiring an additional 36,093 shares in the last quarter. 79.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on AKYA. Stephens reiterated an “equal weight” rating and set a $1.80 price target (down from $3.50) on shares of Akoya Biosciences in a research report on Tuesday, March 25th. Piper Sandler reduced their price target on Akoya Biosciences from $2.40 to $1.65 and set a “neutral” rating for the company in a research report on Monday, April 14th. Finally, Canaccord Genuity Group cut their price objective on Akoya Biosciences from $1.80 to $1.08 and set a “hold” rating for the company in a research report on Monday, May 19th. Seven investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Akoya Biosciences currently has an average rating of “Hold” and a consensus target price of $2.51.

Akoya Biosciences Trading Down 8.8%

Akoya Biosciences stock opened at $1.14 on Wednesday. Akoya Biosciences, Inc. has a 12 month low of $0.93 and a 12 month high of $3.42. The company has a quick ratio of 1.85, a current ratio of 2.75 and a debt-to-equity ratio of 5.62. The business has a 50 day moving average price of $1.19 and a two-hundred day moving average price of $1.88. The stock has a market cap of $56.86 million, a price-to-earnings ratio of -0.97 and a beta of 1.34.

Akoya Biosciences (NASDAQ:AKYA) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.03). The business had revenue of $16.64 million for the quarter, compared to the consensus estimate of $20.19 million. Akoya Biosciences had a negative return on equity of 162.99% and a negative net margin of 66.77%. As a group, equities analysts forecast that Akoya Biosciences, Inc. will post -0.96 EPS for the current year.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.